Amgen Gives up on Its Once-Prized Eczema Drug

Amgen gives up on its once-prized eczema drug

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

New York, Jan 31, 2026, 17:04 EST — Market closed. Amgen shares slipped roughly 0.3% to $341.88 on Friday, barely moving ahead of a busy week packed with catalysts. The biotech is set to unwind its partnership with Japan’s Kyowa Kirin. The near-term setup is crucial as Amgen reports earnings on Tuesday. Investors will focus on which projects the company chooses to fund and which it lets go, given the pipeline’s growing importance in the stock’s …

Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins

Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year. Amgen terminated its ...